Phaseline

Companies › Oruka Therapeutics

Oruka Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Immunology, Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ORKA-001–Phase 2Plaque PsoriasisMay 2027
ORKA-002–Phase 2Plaque Psoriasis; Hidradenitis Suppurativa (HS); Healthy VolunteersOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06944379ORKA-002Phase 1Healthy VolunteersOtherAug 2026
NCT07090330ORKA-001Phase 2Plaque PsoriasisImmunologyMay 2027
NCT07474792ORKA-002Phase 2Plaque PsoriasisImmunologyOct 2027
NCT07783542ORKA-002Phase 2Hidradenitis Suppurativa (HS)ImmunologyOct 2028
NCT07290569ORKA-001Phase 2Plaque PsoriasisImmunologyDec 2028
NCT07449702ORKA-001Phase 2Plaque PsoriasisImmunologyMay 2030

From the company's SEC filings

Cash and short-term investments of $920m on 2026-09-30; operating cash outflow about $136m a year; runway about 81 months at that burn, to Jul 2033; 5 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Palisade Bio Shattuck Labs Spyre Therapeutics Sagimet Biosciences Abivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.